Tinengotinib
A next-generation FGFR inhibitor designed to work after pemigatinib or futibatinib stop working, now in a global phase 3.
Phase 1/2 in heavily pretreated FGFR-altered cholangiocarcinoma, including after prior FGFR inhibitors, showed disease control with median PFS ~5-6 months. FIRST-308 randomises FGFRi-refractory patients to tinengotinib versus FOLFOX/FOLFIRI; first US patient dosed 2025.
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Tinengotinib" OR ABSTRACT:"Tinengotinib" OR TITLE:"TT-00420" OR ABSTRACT:"TT-00420") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tinengotinib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductPemigatinib
Shares FGFR2 fusions and rearrangements, ctDNA-guided switching among FGFR inhibitors, FGFR2, Biliary tract cancer (cholangiocarcinoma).
- ProductFutibatinib
Shares FGFR2 fusions and rearrangements, ctDNA-guided switching among FGFR inhibitors, FGFR2, Biliary tract cancer (cholangiocarcinoma).
- TrialFIGHT-202
- TrialFOENIX-CCA2
- TermIntrahepatic, perihilar, distal and gallbladder cancer
- ProductErdafitinib
Shares FGFR2, Small-molecule kinase inhibitors.
- PersonTanios Bekaii-Saab
- InstitutionNational Cancer Centre Singapore